Solorank.ai
Login

Cached score snapshot

US.ZBH · Zimmer Biomet

110分制 40/110；5D動能v2 6/50；排序分 46/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 46/160
Main score 40/110
5D momentum v2 6/50
Rank #389
Setup grade F 20.8

Score breakdown

避免

Medium twelvedata

Score and price trend

F 20.8 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-17 07-31 09-14 10-05 10-23 $81.47$97.79$114.11 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.34 · anchors 120 +0.79% -1.30% / +3.84% 53.8% 3.8% Actual outcome pending · 0 / 3 bars observed
30D observation +9.25% +1.95% / +14.85% 83.8% 6.3% Actual outcome pending · 0 / 30 bars observed
Historical projection 10D n=160 +0.82% -1.13% / +3.84% 58.1% 2.5% Actual outcome pending · 0 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-17 → 2026-10-23 · 120 archived points · 2 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 46
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 40/110 (避免)
5D momentum v2 6/50 (弱)
Score with momentum v2 46/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 98.6185
ma50 95.332
close 93.49
prevClose 92.44
avgVolume20 1545241
volumeRatio 1.21
changePercent 1.14

Metrics snapshot

close 93.49
volume 1876115
changePercent 1.14

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 40/110
Main rating 避免
5D momentum v2 6/50
Score with momentum v2 46/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.5/5 · 較差
Dimension score 2.5/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.4
epsPoints 0
roePoints 0
debtPoints 0.4
marginPoints 0
turnoverUsdM 175.398
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.4

資金流 — 5.2/20 · 較差
Dimension score 5.2/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 0.8
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.ZBH
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 6.6/15 · 較差
Dimension score 6.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 2.8

details

qqq

ma20 715.668
ma50 710.4064
name QQQ
close 714.88
points 1.4

spy

ma20 766.879
ma50 758.6164
name SPY
close 764.29
points 1.4
source twelvedata+fred
atrPct 2.9208
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 2.8

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 3
catalystCount 0
catalystPoints 2

風險管理 — 6.6/10 · 一般
Dimension score 6.6/10
Dimension grade 一般

Sub-items

position

score 1.4

details

atrPct 2.9208
turnoverUsdM 175.398
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.ZBH
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 88.0286

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 5.8
take_profit_price 99.5431
target_multiplier 1.9
technical_strength 1.75
take_profit_percent 6.5
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.8417
diversificationPoints 2

技術信號 — 13.1/30 · 較差
Dimension score 13.1/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 0.6
macdPoints 0.8

vcpPayload

vcp_pass false
vcp_score 0.6
vcp_reason 跌縮量(近10日5日)；Ready=N；Confirm=N

vcp_metrics

up_days 3
vol_ref 2059920
down_days 6
vcp_ready false
above_ma50 false
avg_vol_10 1579830
avg_vol_20 1582405
avg_vol_30 2059920
range_pct_10 0.122
range_pct_20 0.122
range_pct_30 0.1261
up_expand_ok false
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.7669
dist_to_20d_high 0.0911
down_shrink_days 5
breakout_level_20d 102.86
vcp_breakout_confirm false
contraction_ratio_10_30 0.9678
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 0.8
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 1.2

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 3
negativeHits 0
positiveHits 1
sentimentScoreRaw 0.8

sentimentData

raw {"id":141438330,"url":"https://finnhub.io/api/news?id=243d0ee0172ffa722b31746b8c8e1e05eadb0dfaae61f2ad25155775e0de2e78","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535811,"headline":"Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?"}, {"id":141284711,"url":"https://finnhub.io/api/news?id=c1c85c332d78b720c0e6819943ac8327de2563043775046ae849b4cfb93d007f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...","category":"company","datetime":1787213493,"headline":"Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide"}, {"id":141202570,"url":"https://finnhub.io/api/news?id=343e918e5d609b1ee557aeaf03cdf2ad7202c4c0894816b8625ead88076ce82b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Management raised full-year guidance on strong hip and technology segment growth.","category":"company","datetime":1786543259,"headline":"Zimmer Biomet (ZBH) Q2 2026 Earnings Call Transcript"}
raw_source {"id":142088388,"url":"https://finnhub.io/api/news?id=b65f946b6607896c519b89d20bf3ec3d007ef2e20d136bb2d19e13f251ad3304","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.","category":"company","datetime":1789148345,"headline":"3 Cash-Producing Stocks We Find Risky"}, {"id":142062166,"url":"https://finnhub.io/api/news?id=7bb02a6bb000c69f48be04b21c1244c2f93b6e4e9fa72e06da416c9a15243ddc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation.","category":"company","datetime":1789016441,"headline":"Zimmer restructures Americas leadership team"}, {"id":142029783,"url":"https://finnhub.io/api/news?id=1aa1e22c6ac3142237a0016f4299f278aafa537090db39915324d58d984718f3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.","category":"company","datetime":1788985334,"headline":"How Much Can ISRG Stock Still Move Against You?"}, {"id":141955303,"url":"https://finnhub.io/api/news?id=b70c87d75a047462007b6c4e85fc02b2f136944771e26d34820f28bf539f919e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced leadership appointments designed to streamline its Americas and Global Business Group organizations for greater focus and agility.","category":"company","datetime":1788899400,"headline":"Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation"}, {"id":141956076,"url":"https://finnhub.io/api/news?id=4349f9ccd20bdbdab5eb952f6275997528d354ef55f5807e835a1a7b384e5e85","image":"","source":"Benzinga","related":"ZBH","summary":"Zimmer Biomet also announced today that the Company is reiterating its full-year 2026 financial outlook provided on August 5, 2026.","category":"company","datetime":1788885273,"headline":"Zimmer Biomet Reiterates Its FY 2026 Financial Outlook"}, {"id":140042031,"url":"https://finnhub.io/api/news?id=c81b71ea546004c3a99ae5d5e15eaa1c5c89103783033cbe5b8dccc87646f6fc","image":"","source":"Benzinga","related":"ZBH","summary":"","category":"company","datetime":1788869151,"headline":"Reported Earlier, Medline Prices Secondary Offering Of 75M Class A Shares At $41.00/Share By Blackstone, Carlyle, Hellman & Friedman And ADIA Affiliates"}, {"id":141761420,"url":"https://finnhub.io/api/news?id=4f2802aa4ef24aef7667975d5a4b559ef64630292829d06fe129c3b40461cdab","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.","category":"company","datetime":1788769260,"headline":"Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery"}, {"id":141438330,"url":"https://finnhub.io/api/news?id=243d0ee0172ffa722b31746b8c8e1e05eadb0dfaae61f2ad25155775e0de2e78","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535811,"headline":"Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?"}, {"id":141396710,"url":"https://finnhub.io/api/news?id=65db1ee2f5b674a91bd9cb3aa871658afaa483b35cf9cb04b2c69d8835c6038e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.","category":"company","datetime":1788422838,"headline":"1 Profitable Stock to Keep an Eye On and 2 That Underwhelm"}, {"id":141387139,"url":"https://finnhub.io/api/news?id=76981221810540fa47b2d06c7cbcdbf86f36be642e74beebb26235cab212974e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.","category":"company","datetime":1788390983,"headline":"1 Value Stock with Impressive Fundamentals and 2 We Question"}, {"id":141381193,"url":"https://finnhub.io/api/news?id=2b3549b7f8cb8125eb4f126f266bc4f7b1ff45999bedafe3fbd3f7d0c3d75f3e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.","category":"company","datetime":1788377869,"headline":"ISRG Stock: The Best House On The Block Costs The Most"}, {"id":141360460,"url":"https://finnhub.io/api/news?id=ca436bc4e93675ed50e17876b0cbb895e26e57792fa44fb5659be72650ae38a1","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488373546/image_1488373546.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"ZBH","summary":"Zimmer Biomet sees strong constant currency sales growth driven by transformation, R&D and M&A.","category":"company","datetime":1788255686,"headline":"Zimmer Biomet - Showing Signs Of Life"}, {"id":141365274,"url":"https://finnhub.io/api/news?id=852e4dabed1175dbe4603cf6fc16611cecef4f995471598c402b9e55640f4569","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026. The cash dividend of $0.24 per share is payable on or about October 30, 2026 to stockholders of record as of the close of business on September 30, 2026.","category":"company","datetime":1787951700,"headline":"Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026"}, {"id":141348580,"url":"https://finnhub.io/api/news?id=36696ee64785804f5eca8038825bd6ba269230c62498435b3e9deb757477b06c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.","category":"company","datetime":1787879551,"headline":"Can ISRG Stock Defend Its $131B Valuation?"}, {"id":141362214,"url":"https://finnhub.io/api/news?id=e2458c676c3ad6388cca7f6e19776e30b231a903e390cb33c9f884aa3d2ea765","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.","category":"company","datetime":1787674119,"headline":"The Hospital Bet That Reframes The Intuitive Surgical Stock Story"}, {"id":141278131,"url":"https://finnhub.io/api/news?id=89e11e354106d0898435d7a254123a430d13cfd8b0f361ffc7ad70f19589620f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.","category":"company","datetime":1787338881,"headline":"Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening"}, {"id":141266863,"url":"https://finnhub.io/api/news?id=b7d5cf896bb6d0b75a4e5d1fb1ff72d746322e5429b070564f8d19218b1b8845","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.","category":"company","datetime":1787240400,"headline":"Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?"}, {"id":141262581,"url":"https://finnhub.io/api/news?id=f8a4cc739e42f118d751acb01d597927956e108b45fcd4eabc8bb91e6c7d373f","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229232770/image_2229232770.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"ZBH","summary":"Stryker (SYK) rebounds with 9% organic growth in Q2 as key segments accelerate.","category":"company","datetime":1787231457,"headline":"Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect"}, {"id":141261793,"url":"https://finnhub.io/api/news?id=5e042782fc826f5f9fc4aaf7be41e9dbae91e30d418596850223e9db3e981e89","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283466282/image_2283466282.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"ZBH","summary":"Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Learn more about ENOV stock here.","category":"company","datetime":1787222349,"headline":"Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land"}, {"id":141284711,"url":"https://finnhub.io/api/news?id=c1c85c332d78b720c0e6819943ac8327de2563043775046ae849b4cfb93d007f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...","category":"company","datetime":1787213493,"headline":"Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide"}, {"id":141254019,"url":"https://finnhub.io/api/news?id=5400f530782f025c26084150d8560c68d20f647d699877602be81c7188442c86","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/800341504/image_800341504.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"ZBH","summary":"Smith & Nephew stock is downgraded to 'Hold' amid weak orthopedics, a guidance cut, and exec turnover. Here's what you need to know about SNN.","category":"company","datetime":1787140683,"headline":"Disappointing Ortho Performance Continues To Hold Smith & Nephew Back (Downgrade)"}, {"id":141279326,"url":"https://finnhub.io/api/news?id=df891204872eb2a4f4d7c6b758b4c47f4990d6cef6d8e79cdcc677d8dd98670e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.","category":"company","datetime":1787064840,"headline":"Is ISRG's Software Strategy Becoming as Important as Its Robots?"}, {"id":141243872,"url":"https://finnhub.io/api/news?id=61ee943e8a5ea86e0618df87089dc0f85d75957dfa74acbe00fae233eab250ca","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367003806/image_1367003806.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"ZBH","summary":"Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins. Click here to read why SYK stock is a Hold.","category":"company","datetime":1787015863,"headline":"Stryker Corporation: Hold For Quality, Wait For The Dip"}, {"id":141279652,"url":"https://finnhub.io/api/news?id=8b01bfe77b9eef10584640f034cbf5cbf37525f80ae3a4cfe2e446f8d6e76557","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Supported by real market data through Q4 2025 and 10-year projections, this study delivers a granular evaluation across metal and polymer part categories (prototypes, tooling, end-use production components) and major consuming end-markets, including aerospace giants (GE Aerospace, SpaceX, BAE Systems), medical leaders (Stryker, Zimmer Biomet, Align Technologies), and automotive/tech pioneers (Tesla, Apple, Nvidia).Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The \"AM Applications Analysis: Parts Pro","category":"company","datetime":1786964580,"headline":"AM Applications Analysis: Parts Produced 2025-2034 Delivers 10-Year Additive Manufacturing Market Forecast"}, {"id":141279649,"url":"https://finnhub.io/api/news?id=97e6a3e8c2291d38252a0cd8b0a1ec614aa0faa86db358b8b52fb2680e97211d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.","category":"company","datetime":1786738980,"headline":"SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?"}, {"id":141284712,"url":"https://finnhub.io/api/news?id=1ef2a6c1667211532f78c5a15c70e2526fa4dc30dfba343f3ae676aae632578b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.","category":"company","datetime":1786708129,"headline":"Are Wall Street Analysts Bullish on Zimmer Biomet Stock?"}, {"id":141215562,"url":"https://finnhub.io/api/news?id=e67321f351f15f43154eb2111b6a73bcbcc02aa21cf7c987fbe1d07ab9218997","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform","category":"company","datetime":1786700940,"headline":"5 Revealing Analyst Questions From Zimmer Biomet’s Q2 Earnings Call"}, {"id":141209499,"url":"https://finnhub.io/api/news?id=f663f954f8fee611e7beb5f18947808a333ee8f1f6776a57071730bfce15f675","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.","category":"company","datetime":1786643340,"headline":"Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?"}, {"id":141209498,"url":"https://finnhub.io/api/news?id=ca5d104db49b5d10de5f3c5bcf38982ba3f87b3515925a4a2d6fb7bfc8210a05","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.","category":"company","datetime":1786643340,"headline":"Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?"}, {"id":141209488,"url":"https://finnhub.io/api/news?id=737ffddce8366578aefaee19d208a80c0b1b37e6ef4bbd6db91ed0a2937e91ac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.","category":"company","datetime":1786643340,"headline":"Is SYK Worth Buying as Growth Improves but Execution Risks Persist?"}, {"id":141200509,"url":"https://finnhub.io/api/news?id=e592376329a72805d9a9aeb76b4e614c74226f090c0ad68a111e0bb4d3e4df81","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.","category":"company","datetime":1786570649,"headline":"The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income"}, {"id":141200514,"url":"https://finnhub.io/api/news?id=26115dcb89643ffe9ddf725edb926159cea0317a8a8a874e34930e18eb09dc90","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.","category":"company","datetime":1786555201,"headline":"Two Years Of Growth Barely Change What You Pay For Intuitive Surgical"}, {"id":141202570,"url":"https://finnhub.io/api/news?id=343e918e5d609b1ee557aeaf03cdf2ad7202c4c0894816b8625ead88076ce82b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"ZBH","summary":"Management raised full-year guidance on strong hip and technology segment growth.","category":"company","datetime":1786543259,"headline":"Zimmer Biomet (ZBH) Q2 2026 Earnings Call Transcript"}, {"id":141193278,"url":"https://finnhub.io/api/news?id=357ca417d488522e729cb4788731a4e9c2bf02f33e056d92c95bfe0f40e34f92","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202854526/image_1202854526.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"ZBH","summary":"Intuitive Surgical (ISRG) stock analysis: Hold rating with $426.65 price target (+9% upside).","category":"company","datetime":1786532243,"headline":"Intuitive Surgical: Priced For Precision"}
data_source finnhub_news_keyword_model
article_count 3
negative_hits 0
positive_hits 1
recomputed_at_score true
sentiment_score_raw 0.8
source_article_count 34
discarded_article_count 31
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.5 5/110 50% 2.5
資金流 5.2 20/110 26% 5.2
市場環境 6.6 15/110 44% 6.6
催化劑 2 20/110 10% 2
風險管理 6.6 10/110 66% 6.6
技術信號 13.1 30/110 43.67% 13.1
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 6/50
ret_5d -0.0549
max_score 50
max_total 50
raw_total 6
vcp_bonus 0
vol_ratio 1.1856
ret_points 0
vol_points 2
range_ratio 0.77
volat_points 0
day_range_pct 0.0203
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 4
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.9208
turnoverUsdM 175.398
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.ZBH
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 88.0286

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 5.8
take_profit_price 99.5431
target_multiplier 1.9
technical_strength 1.75
take_profit_percent 6.5
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.8417
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.5/5分
資金流分析總分: 5.2/20分
市場環境分析總分: 6.6/15分
催化劑分析: 2/20分
風險管理總分: 6.6/10分
技術信號分析總分: 13.1/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 71.43
atr
atr 2.7307
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.92
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -180.21
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.0225
kdj
d 24.48
j 8.05
k 19
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 超賣或超買風險
score 2
value 33.93
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 7295315
recentSlope -446178.5
previousSlope 70470
rsi
value 26.16
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 100.501
position SAR喺價上
distancePct 7.5
previousTrend 下降
ma50
value 95.332
macd
macd -0.437
trend 看跌
signal 0.6844
histogram -1.1215
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 98.2749
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.21
score 6
avgVolume 1545241
currentVolume 1876115
derived
ma20 98.6185
ma50 95.332
prevClose 92.44
avgVolume10 1632292
avgVolume20 1545241
changePercent 1.14
avgVolumeForScore 1545241
ma_cross
ma20 98.6185
ma50 95.332
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 98.9225
prevMa50 95.1456
spreadPct 3.45
isVolumeBreakout false
bollinger
lower 93.3213
upper 103.9157
position 中間
rsi_short
value 16.2
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.21

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.920847149427747,
        "turnoverUsdM": 175.39799134999998,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.ZBH",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 88.0286,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.8,
      "take_profit_price": 99.5431,
      "target_multiplier": 1.9,
      "technical_strength": 1.75,
      "take_profit_percent": 6.5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.841694298855494,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 46,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 40,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 6
  },
  "market": {
    "ma20": 98.6185,
    "ma50": 95.332,
    "close": 93.49,
    "prevClose": 92.44,
    "avgVolume20": 1545241,
    "volumeRatio": 1.21,
    "changePercent": 1.14
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 6,
    "details": {
      "ret_5d": -0.054892842701172784,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 6,
      "vcp_bonus": 0,
      "vol_ratio": 1.1856098786341045,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.7700298840697698,
      "volat_points": 0,
      "day_range_pct": 0.020323029200984125,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 46,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 5.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 26,
        "contribution": 5.2
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 13.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 43.67,
        "contribution": 13.1
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 40,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 5.2/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 13.1/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 5.2,
      "市場環境": 6.6,
      "情緒分析": 4,
      "技術信號": 13.1,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 3,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 175.39799134999998,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ZBH",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 715.6679992,
                "ma50": 710.4063990999997,
                "name": "QQQ",
                "close": 714.88,
                "points": 1.4
              },
              "spy": {
                "ma20": 766.87899445,
                "ma50": 758.61640102,
                "name": "SPY",
                "close": 764.28998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.920847149427747,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 3,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.8
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141438330,
                "url": "https://finnhub.io/api/news?id=243d0ee0172ffa722b31746b8c8e1e05eadb0dfaae61f2ad25155775e0de2e78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535811,
                "headline": "Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?"
              },
              {
                "id": 141284711,
                "url": "https://finnhub.io/api/news?id=c1c85c332d78b720c0e6819943ac8327de2563043775046ae849b4cfb93d007f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...",
                "category": "company",
                "datetime": 1787213493,
                "headline": "Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide"
              },
              {
                "id": 141202570,
                "url": "https://finnhub.io/api/news?id=343e918e5d609b1ee557aeaf03cdf2ad7202c4c0894816b8625ead88076ce82b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Management raised full-year guidance on strong hip and technology segment growth.",
                "category": "company",
                "datetime": 1786543259,
                "headline": "Zimmer Biomet (ZBH) Q2 2026 Earnings Call Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142088388,
                "url": "https://finnhub.io/api/news?id=b65f946b6607896c519b89d20bf3ec3d007ef2e20d136bb2d19e13f251ad3304",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
                "category": "company",
                "datetime": 1789148345,
                "headline": "3 Cash-Producing Stocks We Find Risky"
              },
              {
                "id": 142062166,
                "url": "https://finnhub.io/api/news?id=7bb02a6bb000c69f48be04b21c1244c2f93b6e4e9fa72e06da416c9a15243ddc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation.",
                "category": "company",
                "datetime": 1789016441,
                "headline": "Zimmer restructures Americas leadership team"
              },
              {
                "id": 142029783,
                "url": "https://finnhub.io/api/news?id=1aa1e22c6ac3142237a0016f4299f278aafa537090db39915324d58d984718f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.",
                "category": "company",
                "datetime": 1788985334,
                "headline": "How Much Can ISRG Stock Still Move Against You?"
              },
              {
                "id": 141955303,
                "url": "https://finnhub.io/api/news?id=b70c87d75a047462007b6c4e85fc02b2f136944771e26d34820f28bf539f919e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced leadership appointments designed to streamline its Americas and Global Business Group organizations for greater focus and agility.",
                "category": "company",
                "datetime": 1788899400,
                "headline": "Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation"
              },
              {
                "id": 141956076,
                "url": "https://finnhub.io/api/news?id=4349f9ccd20bdbdab5eb952f6275997528d354ef55f5807e835a1a7b384e5e85",
                "image": "",
                "source": "Benzinga",
                "related": "ZBH",
                "summary": "Zimmer Biomet also announced today that the Company is reiterating its full-year 2026 financial outlook provided on August 5, 2026.",
                "category": "company",
                "datetime": 1788885273,
                "headline": "Zimmer Biomet Reiterates Its FY 2026 Financial Outlook"
              },
              {
                "id": 140042031,
                "url": "https://finnhub.io/api/news?id=c81b71ea546004c3a99ae5d5e15eaa1c5c89103783033cbe5b8dccc87646f6fc",
                "image": "",
                "source": "Benzinga",
                "related": "ZBH",
                "summary": "",
                "category": "company",
                "datetime": 1788869151,
                "headline": "Reported Earlier, Medline Prices Secondary Offering Of 75M Class A Shares At $41.00/Share By Blackstone, Carlyle, Hellman & Friedman And ADIA Affiliates"
              },
              {
                "id": 141761420,
                "url": "https://finnhub.io/api/news?id=4f2802aa4ef24aef7667975d5a4b559ef64630292829d06fe129c3b40461cdab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.",
                "category": "company",
                "datetime": 1788769260,
                "headline": "Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery"
              },
              {
                "id": 141438330,
                "url": "https://finnhub.io/api/news?id=243d0ee0172ffa722b31746b8c8e1e05eadb0dfaae61f2ad25155775e0de2e78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535811,
                "headline": "Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?"
              },
              {
                "id": 141396710,
                "url": "https://finnhub.io/api/news?id=65db1ee2f5b674a91bd9cb3aa871658afaa483b35cf9cb04b2c69d8835c6038e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1788422838,
                "headline": "1 Profitable Stock to Keep an Eye On and 2 That Underwhelm"
              },
              {
                "id": 141387139,
                "url": "https://finnhub.io/api/news?id=76981221810540fa47b2d06c7cbcdbf86f36be642e74beebb26235cab212974e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
                "category": "company",
                "datetime": 1788390983,
                "headline": "1 Value Stock with Impressive Fundamentals and 2 We Question"
              },
              {
                "id": 141381193,
                "url": "https://finnhub.io/api/news?id=2b3549b7f8cb8125eb4f126f266bc4f7b1ff45999bedafe3fbd3f7d0c3d75f3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.",
                "category": "company",
                "datetime": 1788377869,
                "headline": "ISRG Stock: The Best House On The Block Costs The Most"
              },
              {
                "id": 141360460,
                "url": "https://finnhub.io/api/news?id=ca436bc4e93675ed50e17876b0cbb895e26e57792fa44fb5659be72650ae38a1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488373546/image_1488373546.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ZBH",
                "summary": "Zimmer Biomet sees strong constant currency sales growth driven by transformation, R&D and M&A.",
                "category": "company",
                "datetime": 1788255686,
                "headline": "Zimmer Biomet - Showing Signs Of Life"
              },
              {
                "id": 141365274,
                "url": "https://finnhub.io/api/news?id=852e4dabed1175dbe4603cf6fc16611cecef4f995471598c402b9e55640f4569",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026. The cash dividend of $0.24 per share is payable on or about October 30, 2026 to stockholders of record as of the close of business on September 30, 2026.",
                "category": "company",
                "datetime": 1787951700,
                "headline": "Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026"
              },
              {
                "id": 141348580,
                "url": "https://finnhub.io/api/news?id=36696ee64785804f5eca8038825bd6ba269230c62498435b3e9deb757477b06c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.",
                "category": "company",
                "datetime": 1787879551,
                "headline": "Can ISRG Stock Defend Its $131B Valuation?"
              },
              {
                "id": 141362214,
                "url": "https://finnhub.io/api/news?id=e2458c676c3ad6388cca7f6e19776e30b231a903e390cb33c9f884aa3d2ea765",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.",
                "category": "company",
                "datetime": 1787674119,
                "headline": "The Hospital Bet That Reframes The Intuitive Surgical Stock Story"
              },
              {
                "id": 141278131,
                "url": "https://finnhub.io/api/news?id=89e11e354106d0898435d7a254123a430d13cfd8b0f361ffc7ad70f19589620f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.",
                "category": "company",
                "datetime": 1787338881,
                "headline": "Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening"
              },
              {
                "id": 141266863,
                "url": "https://finnhub.io/api/news?id=b7d5cf896bb6d0b75a4e5d1fb1ff72d746322e5429b070564f8d19218b1b8845",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.",
                "category": "company",
                "datetime": 1787240400,
                "headline": "Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?"
              },
              {
                "id": 141262581,
                "url": "https://finnhub.io/api/news?id=f8a4cc739e42f118d751acb01d597927956e108b45fcd4eabc8bb91e6c7d373f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229232770/image_2229232770.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ZBH",
                "summary": "Stryker (SYK) rebounds with 9% organic growth in Q2 as key segments accelerate.",
                "category": "company",
                "datetime": 1787231457,
                "headline": "Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect"
              },
              {
                "id": 141261793,
                "url": "https://finnhub.io/api/news?id=5e042782fc826f5f9fc4aaf7be41e9dbae91e30d418596850223e9db3e981e89",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283466282/image_2283466282.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ZBH",
                "summary": "Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Learn more about ENOV stock here.",
                "category": "company",
                "datetime": 1787222349,
                "headline": "Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land"
              },
              {
                "id": 141284711,
                "url": "https://finnhub.io/api/news?id=c1c85c332d78b720c0e6819943ac8327de2563043775046ae849b4cfb93d007f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...",
                "category": "company",
                "datetime": 1787213493,
                "headline": "Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide"
              },
              {
                "id": 141254019,
                "url": "https://finnhub.io/api/news?id=5400f530782f025c26084150d8560c68d20f647d699877602be81c7188442c86",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/800341504/image_800341504.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ZBH",
                "summary": "Smith & Nephew stock is downgraded to 'Hold' amid weak orthopedics, a guidance cut, and exec turnover. Here's what you need to know about SNN.",
                "category": "company",
                "datetime": 1787140683,
                "headline": "Disappointing Ortho Performance Continues To Hold Smith & Nephew Back (Downgrade)"
              },
              {
                "id": 141279326,
                "url": "https://finnhub.io/api/news?id=df891204872eb2a4f4d7c6b758b4c47f4990d6cef6d8e79cdcc677d8dd98670e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.",
                "category": "company",
                "datetime": 1787064840,
                "headline": "Is ISRG's Software Strategy Becoming as Important as Its Robots?"
              },
              {
                "id": 141243872,
                "url": "https://finnhub.io/api/news?id=61ee943e8a5ea86e0618df87089dc0f85d75957dfa74acbe00fae233eab250ca",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367003806/image_1367003806.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ZBH",
                "summary": "Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins. Click here to read why SYK stock is a Hold.",
                "category": "company",
                "datetime": 1787015863,
                "headline": "Stryker Corporation: Hold For Quality, Wait For The Dip"
              },
              {
                "id": 141279652,
                "url": "https://finnhub.io/api/news?id=8b01bfe77b9eef10584640f034cbf5cbf37525f80ae3a4cfe2e446f8d6e76557",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Supported by real market data through Q4 2025 and 10-year projections, this study delivers a granular evaluation across metal and polymer part categories (prototypes, tooling, end-use production components) and major consuming end-markets, including aerospace giants (GE Aerospace, SpaceX, BAE Systems), medical leaders (Stryker, Zimmer Biomet, Align Technologies), and automotive/tech pioneers (Tesla, Apple, Nvidia).Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The \"AM Applications Analysis: Parts Pro",
                "category": "company",
                "datetime": 1786964580,
                "headline": "AM Applications Analysis: Parts Produced 2025-2034 Delivers 10-Year Additive Manufacturing Market Forecast"
              },
              {
                "id": 141279649,
                "url": "https://finnhub.io/api/news?id=97e6a3e8c2291d38252a0cd8b0a1ec614aa0faa86db358b8b52fb2680e97211d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.",
                "category": "company",
                "datetime": 1786738980,
                "headline": "SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?"
              },
              {
                "id": 141284712,
                "url": "https://finnhub.io/api/news?id=1ef2a6c1667211532f78c5a15c70e2526fa4dc30dfba343f3ae676aae632578b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
                "category": "company",
                "datetime": 1786708129,
                "headline": "Are Wall Street Analysts Bullish on Zimmer Biomet Stock?"
              },
              {
                "id": 141215562,
                "url": "https://finnhub.io/api/news?id=e67321f351f15f43154eb2111b6a73bcbcc02aa21cf7c987fbe1d07ab9218997",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform",
                "category": "company",
                "datetime": 1786700940,
                "headline": "5 Revealing Analyst Questions From Zimmer Biomet’s Q2 Earnings Call"
              },
              {
                "id": 141209499,
                "url": "https://finnhub.io/api/news?id=f663f954f8fee611e7beb5f18947808a333ee8f1f6776a57071730bfce15f675",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.",
                "category": "company",
                "datetime": 1786643340,
                "headline": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?"
              },
              {
                "id": 141209498,
                "url": "https://finnhub.io/api/news?id=ca5d104db49b5d10de5f3c5bcf38982ba3f87b3515925a4a2d6fb7bfc8210a05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.",
                "category": "company",
                "datetime": 1786643340,
                "headline": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?"
              },
              {
                "id": 141209488,
                "url": "https://finnhub.io/api/news?id=737ffddce8366578aefaee19d208a80c0b1b37e6ef4bbd6db91ed0a2937e91ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.",
                "category": "company",
                "datetime": 1786643340,
                "headline": "Is SYK Worth Buying as Growth Improves but Execution Risks Persist?"
              },
              {
                "id": 141200509,
                "url": "https://finnhub.io/api/news?id=e592376329a72805d9a9aeb76b4e614c74226f090c0ad68a111e0bb4d3e4df81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.",
                "category": "company",
                "datetime": 1786570649,
                "headline": "The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income"
              },
              {
                "id": 141200514,
                "url": "https://finnhub.io/api/news?id=26115dcb89643ffe9ddf725edb926159cea0317a8a8a874e34930e18eb09dc90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.",
                "category": "company",
                "datetime": 1786555201,
                "headline": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical"
              },
              {
                "id": 141202570,
                "url": "https://finnhub.io/api/news?id=343e918e5d609b1ee557aeaf03cdf2ad7202c4c0894816b8625ead88076ce82b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ZBH",
                "summary": "Management raised full-year guidance on strong hip and technology segment growth.",
                "category": "company",
                "datetime": 1786543259,
                "headline": "Zimmer Biomet (ZBH) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141193278,
                "url": "https://finnhub.io/api/news?id=357ca417d488522e729cb4788731a4e9c2bf02f33e056d92c95bfe0f40e34f92",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202854526/image_1202854526.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ZBH",
                "summary": "Intuitive Surgical (ISRG) stock analysis: Hold rating with $426.65 price target (+9% upside).",
                "category": "company",
                "datetime": 1786532243,
                "headline": "Intuitive Surgical: Priced For Precision"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 3,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.8,
            "source_article_count": 34,
            "discarded_article_count": 31
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13.1,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.6,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.6,
            "vcp_reason": "跌縮量(近10日5日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 2059920,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 1579830,
              "avg_vol_20": 1582405,
              "avg_vol_30": 2059920,
              "range_pct_10": 0.12204513851748847,
              "range_pct_20": 0.12204513851748847,
              "range_pct_30": 0.12610974435768538,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7669375509728533,
              "dist_to_20d_high": 0.09109469181411632,
              "down_shrink_days": 5,
              "breakout_level_20d": 102.86,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.9677692960135701
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.920847149427747,
              "turnoverUsdM": 175.39799134999998,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.ZBH",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 88.0286,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.8,
            "take_profit_price": 99.5431,
            "target_multiplier": 1.9,
            "technical_strength": 1.75,
            "take_profit_percent": 6.5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.841694298855494,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.ZBH",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 2.7307,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.92
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -180.21
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0225
    },
    "kdj": {
      "d": 24.48,
      "j": 8.05,
      "k": 19,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 33.93
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 7295315,
      "recentSlope": -446178.5,
      "previousSlope": 70470
    },
    "rsi": 26.16,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 100.501,
      "position": "SAR喺價上",
      "distancePct": 7.5,
      "previousTrend": "下降"
    },
    "ma50": 95.332,
    "macd": {
      "macd": -0.43703020874140464,
      "trend": "看跌",
      "signal": 0.6844200493241603,
      "histogram": -1.121450258065565
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 98.2749,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.21,
      "score": 6,
      "avgVolume": 1545241,
      "currentVolume": 1876115
    },
    "derived": {
      "ma20": 98.6185,
      "ma50": 95.332,
      "prevClose": 92.44,
      "avgVolume10": 1632292,
      "avgVolume20": 1545241,
      "changePercent": 1.14,
      "avgVolumeForScore": 1545241
    },
    "ma_cross": {
      "ma20": 98.6185,
      "ma50": 95.332,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 98.9225,
      "prevMa50": 95.1456,
      "spreadPct": 3.45,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 93.3213,
      "upper": 103.9157,
      "position": "中間"
    },
    "rsi_short": 16.2,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.21
    }
  }
}

Raw metrics JSON

 
{
  "close": 93.49,
  "volume": 1876115,
  "changePercent": 1.14
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.